Trial Profile
Study of Daratumumab in Combination with Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD) in the First Line Treatment of Transplant Eligible Subjects with Newly Diagnosed Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Thalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms CASSIOPEIA
- 12 Dec 2023 Results (n=49) demonstrating NK cell profiles association with minimal residual disease (MRD) negativity in NDMM patients treated with D-VTD in in conjunction with ASCT, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 This trial has been completed in Netherlands (End Date: 01 Sep 2023), according to European Clinical Trials Database record.
- 30 Nov 2023 This trial has been completed in Belgium according to European Clinical Trials Database record.